Michael Secora - Feb 4, 2022 Form 4/A - Amendment Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role
Chief Financial Officer
Signature
/s/ Jonathan Golightly, attorney-in-fact
Stock symbol
RXRX
Transactions as of
Feb 4, 2022
Transactions value $
-$7,729
Form type
4/A - Amendment
Date filed
4/28/2023, 04:30 PM
Date Of Original Report
Feb 8, 2022
Next filing
May 18, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXRX Class A Common Stock Award $0 +58.3K +10.99% $0.00 589K Feb 4, 2022 Direct F1, F2
transaction RXRX Class A Common Stock Award $0 +1.96K +0.33% $0.00 591K Feb 4, 2022 Direct F2, F3
transaction RXRX Class A Common Stock Tax liability -$7.73K -678 -0.11% $11.40 590K Feb 4, 2022 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This RSU vests as to one one-sixteenth (1/16th) of the units subject the RSU on May 15, 2022 and every three months thereafter.
F2 Includes 1,388 shares purchased pursuant to the Issuer's Employee Stock Purchase Plan on November 22, 2021 and 609 shares received pursuant to a pro rata distribution from Catalio Nexus Fund II, LP, of which the Reporting Person was a limited partner (the acquisition of such shares from Catalio was inadvertently excluded from the total shares held in the original Form 4 filing and is exempt pursuant to Rule 16a-9).
F3 This RSU vested immediately upon the grant date.